Immunovant Inc 2024年度报告

FORM10-K (MarkOne) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the fiscal year endedMarch 31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from _____ to _____Commission File Number:001-38906 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) 83-2771572 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 320 West 37th Street10018New York,NY(Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (917)580-3099 Securities registered pursuant to Section12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchangeon which registered Securities registered pursuant to section12(g) of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the SecuritiesAct.Yes☒No☐ Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).Yes☐No☒ The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant, based on the closing price of theregistrant’s common stock on The Nasdaq Global Select Market as of September 30, 2024,the last business day of the registrant’smost recently completed second fiscal quarter,was approximately $1,866.6million, based on the closing price of the registrant’scommon stock on The Nasdaq Global Select Market of $28.51 per share. As of May23, 2025, the registrant had170,923,191shares of common stock, $0.0001 par value per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III ofthis Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and ExchangeCommission within 120 days of the registrant’s fiscal year ended March31, 2025. IMMUNOVANT, INC.ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS PART IITEM 1. BUSINESS7ITEM 1A. RISK FACTORS47ITEM 1B. UNRESOLVED STAFF COMMENTS98ITEM 1C. CYBERSECURITY98ITEM 2. PROPERTIES99ITEM 3. LEGAL PROCEEDINGS99ITEM 4. MINE SAFETY DISCLOSURES99PART IIITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS ANDISSUER PURCHASES OF EQUITY SECURITIES100ITEM 6. [RESERVED]101ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS102ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK115ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA116ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIALDISCLOSURE141ITEM 9A. CONTROLS AND PROCEDURES141ITEM 9B. OTHER INFORMATION143ITEM 9C. DISCLOSURE RE